35217-95-9

Basic information

• Product Name: 4-OXIRANYLMETHOXY-BENZOIC ACID
• Synonyms: 4-OXIRANYLMETHOXY-BENZOIC ACID;RARECHEM AL BE 1118;2-[(4-Carboxyphenoxy)methyl]oxirane, 3-(4-Carboxyphenoxy)-1,2-propenoxide;4-(2-Oxiranylmethoxy)benzoic acid
• CAS NO: 35217-95-9
• Molecular Formula: C₁₀H₁₀O₄
• Molecular Weight: 194.18
• Product Categories: pharmacetical
• Mol File: 35217-95-9.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-OXIRANYLMETHOXY-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-OXIRANYLMETHOXY-BENZOIC ACID(35217-95-9)
• EPA Substance Registry System: 4-OXIRANYLMETHOXY-BENZOIC ACID(35217-95-9)

Safety Data

• Hazard Codes: T
• Hazardous Substances Data: 35217-95-9(Hazardous Substances Data)

Usage

General Description

4-OXIRANYLMETHOXY-BENZOIC ACID is a chemical compound with the molecular formula C9H8O4. It is a derivative of benzoic acid, containing an oxirane group and a methoxy group. 4-OXIRANYLMETHOXY-BENZOIC ACID is often used in organic synthesis and pharmaceutical research as an intermediate or starting material for the production of various compounds. It has also been investigated for its potential biological and pharmacological effects, including anti-inflammatory and anti-cancer activities. Its precise uses and applications may vary depending on the specific chemical and pharmaceutical research being conducted.

Upstream product

• 5535-03-5 methyl rac-4-(oxiran-2-ylmethoxy)benzoate 
• 2186-24-5 cresyl-glicidyl ether 
• 3132-64-7 1,2-Epoxy-3-bromopropane 
• 2345-34-8 4-acetyloxy-benzoic acid 
• 123-08-0 4-hydroxy-benzaldehyde 
• 14697-49-5 4-(2,3-epoxy)propyloxybenzaldehyde 
• 50625-94-0 ethyl 4-(glycidyloxy)benzoate 
• 106-89-8 epichlorohydrin 
• 99-96-7 4-hydroxy-benzoic acid 

Downstream Products

• 1165820-52-9 C₇₅H₁₁₉N₅O₃₇ 
• 147538-71-4 2-[3-[(p-carboxy)-phenoxy]-2-hydroxy-propylthio]-benzothiazole 

Relevant articles and documents

Stepwise benzylic oxygenation via uranyl-photocatalysis

Stepwise oxygenation at the benzylic position (1°, 2°, 3°) of aromatic molecules was comprehensively established under ambient conditions via uranyl photocatalysis to produce carboxylic acids, ketones, and alcohols, respectively. The accuracy of the stepwise oxygenation was ensured by the tunability of catalytic activity in uranyl photocatalysis, which was adjusted by solvents and additives demonstrated through Stern–Volmer analysis. Hydrogen atom transfer between the benzylic position and the uranyl catalyst facilitated oxygenation, further confirmed by kinetic studies. Considerably improved efficiency of flow operation demonstrated the potential for industrial synthetic application.

Crystal structures of 4-(oxiran-2-ylmethoxy) benzoic acid and 4-acetoxybenzoic acid

Compounds 4-(oxiran-2-ylmethoxy)benzoic acid (2) and 4-acetoxybenzoic acid (4) are synthesized by a new synthetic route and studied by X-ray crystallography. Compound 2 crystallizes in the monoclinic system, P21/n space group, a = 5.1209(2) A, b = 30.3429(16) A, c = 5.9153(3) A, β = 96.725(3)°, V = 912.81(8) A3, Z = 4. Compound 4 crystallizes in the triclinic system, P-1 space group, a = 7.3400(4) A, b = 8.0819(3) A, c = 15.6548(9) A, α = 85.754(3)°, β = 84.268(2)°, γ = 70.023(3)°, V = 867.63(8) A3, Z = 4. The crystal structure of 2 comprises two crystallographically independent molecules of the compound. In the crystal structures of 2 and 4, pairs of molecules form carboxyl dimers. Original Russian Text Copyright

8-Substituted purine derivatives: a new class of lipid-lowering agents

A series of purine derivatives have been prepared and their in vivo abilities to lower plasma total cholesterol and triglyceride levels, and to elevate high density lipoprotein (HDL) cholesterol levels in hyperlipemic rats have been tested.Some compounds, among which 8-propylthio>adenosine 31, 8--2-oxopropylthio>adenosine 33 and 8--2-hydrazonecarboxamidepropylthio>adenosine 36 appear to be the most interesting, have been found to have both the desired profile of activity and no hepatotoxicity, when administered po at 50, 100 or 300 mg/kg.Compounds 31, 33 and 36, orally tested at the same doses in the 15-d test, lower triglyceride and VLDL/LDL (very low density lipoprotein / low density lipoprotein) cholesterol levels by 10-33percent and 13-46percent, respectively, and increase HDL-associated cholesterol levels by 10-32percent.These molecules have been chosen for further pharmacological and toxicological evaluations. adenosine / purine / cholesterol / triglyceride / hypolipemic agent